Actually, the combination of trastuzumab with either lapatinib or pertuzumab is being tested in a pioneer phase II study enrolling KRAS wild-type CRC patients harboring amplification of the HER-2 oncogene that have run out of options [60]. This evidence concerns the gene ERBB2 and colorectal carcinoma.